Information Provided By: 
Fly News Breaks for December 17, 2018
BAX
Dec 17, 2018 | 16:35 EDT
Credit Suisse analyst Matt Miksic initiated Baxter with an Outperform rating and a price target of $77 as part of his broader research note on Medical Supplies and Devices partially titled "No Disruption, No Alpha". The analyst believes that the company can get back on track in 2019 and that the stock is attractively priced, also forecasting over 600bps of margin improvement since 2015. Miksic also cites the company's plans to launch over 50 new products in multiple geographies over the next 5 yeas.
News For BAX From the Last 2 Days
There are no results for your query BAX
